GLPwatch
Liraglutide and Cardio-Metabolic Risk Markers
NCT01715428 · Completed
Last updated 2026-05-28This clinical trial tests whether the medication liraglutide affects heart and blood vessel health in adults with type 2 diabetes.
Status Completed The study has finished.
Type Observational
Participants 300 people
Who can join Ages 18–80 · all sexes
Timeline Started 2012-06 · est. completion 2015-12
Where 1 site · Italy
What this study is testing ClinicalTrials.gov NCT01715428 ↗
Description as written by the study sponsor.
Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.
| Main thing measured | carotid intima-media thickness |
|---|---|
| Sponsor | University of Palermo |
| Conditions studied | Type-2 Diabetes |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01715428 ↗